Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 67,484 shares at $65.72 ($4.6M) on 2026-06-04, disclosed to the SEC on 2026-06-08.
Scheduled sale ($4.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.72 | 2,200 | $145K | 3.2% |
| 2 | $66.72 | 1,429 | $95K | 2.1% |
| 3 | $67.74 | 15,921 | $1.1M | 23.6% |
| 4 | $67.74 | 15,921 | $1.1M | 23.6% |
| 5 | $68.27 | 450 | $31K | 0.7% |
| 6 | $67.20 | 7,147 |
| $480K |
| 10.5% |
| 7 | $67.20 | 7,148 | $480K | 10.5% |
| 8 | $67.88 | 8,437 | $573K | 12.5% |
| 9 | $68.96 | 4,416 | $305K | 6.7% |
| 10 | $68.96 | 4,415 | $304K | 6.7% |
| Total | $67.72 avg | 67,484 | $4.6M | 100% |
| Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |
| BBIO | SELL | 2026-04-13 | $6.0M | — | Filing → |